~~<i id='F90590CC2C'><strike id='F90590CC2C'><tt id='F90590CC2C'><pre id='F90590CC2C'></pre></tt></strike></i>~~

Home» Wikipedia» hotspot

hotspot

author：knowledge 2025-09-28 15:44:41 Page View：1747

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs
Next article： Psychedelics group wrestles with new pharma identity

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

At ASCO, AstraZeneca reports strong data for breast cancer drug

ThefuturelooksevenbrighterfortheblockbusterEnhertu,showcasedhereatASCO.ADAMFEUERSTEIN/STATCHICAGO—Th

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

Shifting the focus from loneliness to social health

AdobeIt’sbeenoneyearsincetheU.S.surgeongeneralissuedanationalwarningaboutanepidemicofloneliness.Othe